0000000000530773

AUTHOR

Kai C. Wollert

showing 3 related works from this author

C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-R…

2019

Background: Acute myocardial infarction (MI) elicits an inflammatory response that drives tissue repair and adverse cardiac remodeling. Inflammatory cell trafficking after MI is controlled by C-X-C motif chemokine ligand 12 (CXCL12) and its receptor, C-X-C motif chemokine receptor 4 (CXCR4). CXCR4 antagonists mobilize inflammatory cells and promote infarct repair, but the cellular mechanisms are unclear. Methods: We investigated the therapeutic potential and mode of action of the peptidic macrocycle CXCR4 antagonist POL5551 in mice with reperfused MI. We applied cell depletion and adoptive transfer strategies using lymphocyte-deficient Rag1 knockout mice; DEREG mice, which express a diphth…

Receptors CXCR4Regulatory T cellCXCR4 antagonistSus scrofaAnti-Inflammatory AgentsMyocardial InfarctionNeovascularization PhysiologicMice TransgenicInflammation030204 cardiovascular system & hematologyT-Lymphocytes RegulatoryVentricular Function Left03 medical and health sciencesChemokine receptor0302 clinical medicineImmune systemPhysiology (medical)medicineAnimalsMyocardial infarction030304 developmental biology0303 health sciencesMobilizationVentricular Remodelingbusiness.industryMyocardiumProteinsDendritic CellsRecovery of FunctionRegulatory T cellsTissue repairmedicine.diseaseMyocardial ContractionBlockadeMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureCancer researchmedicine.symptomCardiology and Cardiovascular MedicinebusinessSignal TransductionCirculation
researchProduct

Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.

2016

Heart failure (HF) incidence is rising worldwide and HF with preserved ejection fraction (HFpEF) represents nearly half of all cases. Treatment options are still limited in HFpEF in comparison to HF with reduced ejection fraction (HFrEF).We analyzed biomarkers in the general population to characterize HFpEF and HFrEF and defined a biomarker index to differentiate HFpEF from HFrEF. Growth differentiation factor-15 (GDF-15), soluble source of tumorigenicity 2 (sST2), C-reactive protein (CRP) and NT-proBNP were measured in 5000 individuals of the population-based Gutenberg Health Study (GHS). The median follow-up time for all-cause mortality was 7.3years with 213 events.Identification of subje…

AdultMalemedicine.medical_specialtyGrowth Differentiation Factor 15Population030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicineNatriuretic Peptide BrainmedicineHumans030212 general & internal medicineeducationAgedHeart Failureeducation.field_of_studyEjection fractionbiologybusiness.industryIncidence (epidemiology)C-reactive proteinTreatment optionsStroke VolumeMiddle Agedmedicine.diseasePrognosisInterleukin-1 Receptor-Like 1 ProteinPeptide FragmentsC-Reactive ProteinHeart failurebiology.proteinCardiologyBiomarker (medicine)FemaleGDF15Cardiology and Cardiovascular MedicinebusinessBiomarkersInternational journal of cardiology
researchProduct

Multiple marker approach to risk stratification in patients with stable coronary artery disease

2010

Aims Multimarker approaches for risk prediction in coronary artery disease have remained inconsistent. We assessed multiple biomarkers representing distinct pathophysiological pathways in relation to cardiovascular events in stable angina. Methods and results We investigated 12 biomarkers reflecting inflammation [C-reactive protein, growth-differentiation factor (GDF)-15, neopterin], lipid metabolism (apolipoproteins AI, B100), renal function (cystatin C, serum creatinine), and cardiovascular function and remodelling [copeptin, C-terminal-pro-endothelin-1, mid-regional-pro-adrenomedullin (MR-proADM), mid-regional-pro-atrial natriuretic peptide (MR-proANP), N-terminal-pro-B-type natriuretic …

Malemedicine.hormonemedicine.medical_specialtymedicine.drug_classMyocardial InfarctionCoronary Artery DiseaseKaplan-Meier EstimateRisk AssessmentAnginaCoronary artery diseaseEndothelinsCopeptinInternal medicinemedicineNatriuretic peptideHumansAngina StableProspective StudiesRisk factorAgedbiologybusiness.industryHazard ratioMiddle AgedPrognosismedicine.diseaseEndocrinologyCystatin Cbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean Heart Journal
researchProduct